154 related articles for article (PubMed ID: 24494692)
1. Managed care implications in castration-resistant prostate cancer.
Lew I
Am J Manag Care; 2013 Dec; 19(18 Suppl):s376-81. PubMed ID: 24494692
[TBL] [Abstract][Full Text] [Related]
2. Current state of castration-resistant prostate cancer.
Petrylak DP
Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
4. Current, new and novel therapy for castration-resistant prostate cancer.
Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
[TBL] [Abstract][Full Text] [Related]
5. Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer.
Garje R; Chennamadhavuni A; Mott SL; Chambers IM; Gellhaus P; Zakharia Y; Brown JA
Clin Genitourin Cancer; 2020 Apr; 18(2):e157-e166. PubMed ID: 31956009
[TBL] [Abstract][Full Text] [Related]
6. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
Saad F; Fizazi K
Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
[TBL] [Abstract][Full Text] [Related]
7. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
Anantharaman A; Small EJ
Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
[TBL] [Abstract][Full Text] [Related]
8. Novel agents for the management of castration-resistant prostate cancer.
Haddad H; Garcia JA
Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
[TBL] [Abstract][Full Text] [Related]
9. [New therapies in metastatic castration resistant prostate cancer].
Thibault C; Massard C
Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
[TBL] [Abstract][Full Text] [Related]
10. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
11. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
Akaza H
Nihon Rinsho; 2014 Dec; 72(12):2108-15. PubMed ID: 25518342
[TBL] [Abstract][Full Text] [Related]
12. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
13. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
14. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer.
Thelen P; Wuttke W; Seidlová-Wuttke D
J Steroid Biochem Mol Biol; 2014 Jan; 139():290-3. PubMed ID: 23872207
[TBL] [Abstract][Full Text] [Related]
15. [New era of the treatment of CRPC in Japan].
Akaza H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):804. PubMed ID: 25131863
[TBL] [Abstract][Full Text] [Related]
16. New developments in the treatment of castration resistant prostate cancer.
Wadia R; Petrylak DP
Asian J Androl; 2014; 16(4):555-60. PubMed ID: 24759588
[TBL] [Abstract][Full Text] [Related]
17. [Changes in the treatment of metastatic prostate cancer-new data and open questions].
Albers P; Bögemann M; Machtens S; Merseburger AS; Schostak M; Steuber T; Wülfing C; De Santis M
Urologe A; 2020 Mar; 59(3):307-317. PubMed ID: 31781782
[TBL] [Abstract][Full Text] [Related]
18. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
20. GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer.
Naiki T; Naiki-Ito A; Asamoto M; Kawai N; Tozawa K; Etani T; Sato S; Suzuki S; Shirai T; Kohri K; Takahashi S
Carcinogenesis; 2014 Sep; 35(9):1962-7. PubMed ID: 24562575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
